← Leaderboards
Anthony O Caggiano
Cognition Therapeutics, Inc.
$51,394,003
Attributed
$99,057,723
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $40.7M · FY2005–25$50M$37.5M$25M$12.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$99,057,723 · 10
By mechanism
R01$88,888,107 · 3
RF1$5,445,051 · 1
SB1$1,642,783 · 1
U01$1,366,849 · 1
P20$1,270,094 · 1
R43$444,839 · 3
Top collaborators
- Paul S. Aisen3 shared
- James E Galvin3 shared
- Mary E Hamby3 shared
- Christopher H Van Dyck3 shared
- Nancy Joan Brown2 shared
- Douglas L Rosene2 shared
- Douglas B Sawyer2 shared
Most similar at Cognition Therapeutics, Inc.
Same institution · by research overlap
- Nicholas John Izzo$4,437,830
- Susan M Catalano$36,630,926
- Paul S. Aisen$209,920,520
- Christopher H Van Dyck$43,230,259
- Mary E Hamby$9,832,688
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposDoseBrainSafetyNeuronsAbeta OligomerS DiseaseSmall MoleculeCerebrospinal FluidSynapsesCognitionReceptorDesignDrug CandidateS Disease PatientClinical TrialsPharmaceutical PreparationsAmyloid Beta-ProteinDouble-Blind MethodRandomizedCognitive FunctionNeurograninBindingPlacebos
Grant awards (19)
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$11,955,061
R01 · FY2025 · AG · contact PI
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$13,127,747
R01 · FY2024 · AG · contact PI
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$8,479,107
R01 · FY2023 · AG · contact PI
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$10,254,288
R01 · FY2022 · AG · contact PI
A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimerʼs Disease$2,144,409
RF1 · FY2022 · AG · contact PI
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$14,619,478
R01 · FY2021 · AG · contact PI
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimerʼs Disease$13,634,548
R01 · FY2021 · AG · contact PI
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$10,764,669
R01 · FY2021 · AG · contact PI
Human AME study of CT1812, a small molecule in phase 2 clinical trials for the treatment of Alzheimer's disease$1,642,783
SB1 · FY2021 · AG · contact PI
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease$5,774,586
R01 · FY2020 · AG · contact PI
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease$278,623
R01 · FY2020 · AG · contact PI
A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimerʼs Disease$3,300,642
RF1 · FY2019 · AG · contact PI
Translational Development of Glial Growth Factor 2 (GGF2) for the Treatment of St$889,977
U01 · FY2016 · NS · contact PI
Translational Development of Glial Growth Factor 2 (GGF2) for the Treatment of St$476,872
U01 · FY2014 · NS · contact PI
Recombinant Neuregulin for the treatment of Heart Failure$596,673
P20 · FY2011 · HL
Recombinant Neuregulin for the treatment of Heart Failure$673,421
P20 · FY2010 · HL
Molecular Evolution of Chondroitinase ABCI for SCI$184,388
R43 · FY2005 · NS
Chimeric proteins for the treatment of spinal cord injury$153,151
R43 · FY2005 · NS
Release Chondroitinase Systems for Spinal Cord Injury$107,300
R43 · FY2003 · NS